leisure time -WSS

leisure time

author：focus 2025-10-02 21:00:43 - browse：1295

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Trump's false claims about Georgia's 2020 election long debunked

WSS

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Baltimore teen accused of firing into crowd during block party mass shooting

Cancer drug shortages' outsize impact on ovarian cancer patients

Baltimore teen accused of firing into crowd during block party mass shooting

Eye stem cell transplant could help restore vision in injured people

ActiGraph execs on goal of drug approvals with digital endpoints

entertainment

leisure time

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

Majority of Americans think Trump's Ga. election interference case is serious: POLL

The high cost of giving birth even with insurance

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Trump's false claims about Georgia's 2020 election long debunked

Hepatitis C has a cure — but many Americans still lack access to it

GOP inquiry over gain

Heart attack and stroke risk calculators need revising

Here's how to stay safe from wildfire smoke amid reduced air quality

explore

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Thousands protest in Iraq for a second day over burning of Quran in Sweden

Clinical trials must include more disabled people

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Congress must give Medicare recipients genetic counseling access

Illumina to lay off 10% of research and development team

hotspot

entertainment

leisure time

focus